Twist Bioscience (TWST)
(Delayed Data from NSDQ)
$42.37 USD
-0.83 (-1.92%)
Updated May 10, 2024 04:00 PM ET
After-Market: $42.40 +0.03 (0.07%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth B Momentum C VGM
Twist Bioscience (TWST) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$43.38 | $55.00 | $28.00 | 0.42% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Twist Bioscience comes to $43.38. The forecasts range from a low of $28.00 to a high of $55.00. The average price target represents an increase of 0.42% from the last closing price of $43.20.
Analyst Price Targets (8 )
Broker Rating
Twist Bioscience currently has an average brokerage recommendation (ABR) of 1.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.67 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, seven are Strong Buy, representing 77.78% of all recommendations. A month ago, Strong Buy represented 77.78%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 1.67 | 1.67 | 1.67 | 1.67 | 1.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/7/2024 | Scotiabank | Sung-Ji Nam | Strong Buy | Strong Buy |
5/3/2024 | William Blair | Matt Larew | Strong Buy | Strong Buy |
5/3/2024 | Robert W. Baird & Co. | Catherine W Schulte | Strong Buy | Strong Buy |
5/3/2024 | Evercore Partners | Vijay Kumar | Strong Buy | Strong Buy |
2/2/2024 | SVB Securities | Puneet Souda | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.67 |
ABR (Last week) | 1.67 |
# of Recs in ABR | 9 |
Average Target Price | $43.38 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 252 |
Current Quarter EPS Est: | -0.80 |